RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.50 Consensus PT from Brokerages

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has received a consensus rating of “Hold” from the thirteen analysts that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.50.

RAPT has been the subject of several recent analyst reports. JPMorgan Chase & Co. cut shares of RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Monday, November 11th. Wells Fargo & Company reduced their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $8.00 to $2.00 in a report on Monday, November 11th. HC Wainwright reaffirmed a “neutral” rating on shares of RAPT Therapeutics in a research note on Tuesday, November 12th. Finally, UBS Group decreased their target price on RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th.

RAPT Therapeutics Trading Down 13.7 %

Shares of RAPT stock opened at $1.11 on Friday. The stock has a 50 day simple moving average of $1.93 and a 200-day simple moving average of $2.92. The company has a market cap of $38.63 million, a price-to-earnings ratio of -0.40 and a beta of 0.33. RAPT Therapeutics has a 12-month low of $1.03 and a 12-month high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.09. On average, equities analysts forecast that RAPT Therapeutics will post -2.8 earnings per share for the current fiscal year.

Institutional Trading of RAPT Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RAPT. Hennion & Walsh Asset Management Inc. raised its stake in RAPT Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock valued at $148,000 after purchasing an additional 3,824 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of RAPT Therapeutics in the first quarter valued at approximately $97,000. EntryPoint Capital LLC purchased a new position in shares of RAPT Therapeutics during the first quarter valued at approximately $161,000. Readystate Asset Management LP acquired a new stake in RAPT Therapeutics during the third quarter worth approximately $36,000. Finally, Bank of New York Mellon Corp grew its stake in RAPT Therapeutics by 24.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 114,590 shares of the company’s stock worth $349,000 after acquiring an additional 22,175 shares during the period. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.